JPWO2020120979A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020120979A5 JPWO2020120979A5 JP2021534207A JP2021534207A JPWO2020120979A5 JP WO2020120979 A5 JPWO2020120979 A5 JP WO2020120979A5 JP 2021534207 A JP2021534207 A JP 2021534207A JP 2021534207 A JP2021534207 A JP 2021534207A JP WO2020120979 A5 JPWO2020120979 A5 JP WO2020120979A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide ligand
- seq
- fapα
- peptide
- cysteine residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 239000003446 ligand Substances 0.000 description 16
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 5
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820320.8 | 2018-12-13 | ||
| GBGB1820320.8A GB201820320D0 (en) | 2018-12-13 | 2018-12-13 | Bicyclic peptide ligands specific for FAPalpha |
| PCT/GB2019/053535 WO2020120979A1 (en) | 2018-12-13 | 2019-12-13 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPα |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515721A JP2022515721A (ja) | 2022-02-22 |
| JPWO2020120979A5 true JPWO2020120979A5 (enExample) | 2022-12-19 |
Family
ID=65147028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534207A Pending JP2022515721A (ja) | 2018-12-13 | 2019-12-13 | ＦＡＰαに特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220008545A1 (enExample) |
| EP (1) | EP3894005A1 (enExample) |
| JP (1) | JP2022515721A (enExample) |
| CN (1) | CN113507961A (enExample) |
| GB (1) | GB201820320D0 (enExample) |
| WO (1) | WO2020120979A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| CN111118063B (zh) * | 2019-12-05 | 2023-04-18 | 吉林大学 | 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003293311A1 (en) * | 2002-09-18 | 2004-04-23 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| US7374898B2 (en) * | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| EP1844337B1 (en) | 2005-01-24 | 2013-07-03 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| US20100047170A1 (en) * | 2006-01-05 | 2010-02-25 | Denmeade Samuel R | Peptide Prodrugs |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| CN108383893A (zh) * | 2011-08-30 | 2018-08-10 | 塔夫茨大学信托人 | 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂 |
| RU2708459C2 (ru) | 2014-10-29 | 2019-12-09 | БайсиклРД Лимитед | Бициклические пептидные лиганды, специфичные для мт1-ммр |
| WO2016146174A1 (en) * | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| US10857196B2 (en) * | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
-
2018
- 2018-12-13 GB GBGB1820320.8A patent/GB201820320D0/en not_active Ceased
-
2019
- 2019-12-13 US US17/309,628 patent/US20220008545A1/en not_active Abandoned
- 2019-12-13 EP EP19823955.0A patent/EP3894005A1/en not_active Withdrawn
- 2019-12-13 WO PCT/GB2019/053535 patent/WO2020120979A1/en not_active Ceased
- 2019-12-13 CN CN201980089032.4A patent/CN113507961A/zh active Pending
- 2019-12-13 JP JP2021534207A patent/JP2022515721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6223377B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| JP2018171063A5 (enExample) | ||
| JPWO2021019243A5 (enExample) | ||
| JP2011502964A5 (enExample) | ||
| JP2006514607A5 (enExample) | ||
| JPWO2020148525A5 (enExample) | ||
| JP2007534698A5 (enExample) | ||
| JPWO2021019244A5 (enExample) | ||
| JP2011518179A5 (enExample) | ||
| JP2006514104A5 (enExample) | ||
| JPWO2020148526A5 (enExample) | ||
| JPWO2020120980A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JPWO2020120981A5 (enExample) | ||
| JPWO2020128527A5 (enExample) | ||
| JP2010536714A5 (enExample) | ||
| JP2020526497A5 (enExample) | ||
| Redman et al. | Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery | |
| WO2002020561A1 (en) | Novel polypeptides and anti-hiv drugs containing the same | |
| JPWO2020148528A5 (enExample) | ||
| JPWO2020148529A5 (enExample) | ||
| JPWO2020120983A5 (enExample) | ||
| JPWO2019204206A5 (enExample) | ||
| JPWO2020148527A5 (enExample) | ||
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 |